Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteMark Cuban’s best-documented major business outcomes include Broadcast.com’s sale to Yahoo and the Dallas Mavericks’ 2023 control sale—but public figures do not establish a definitive ranking of his personal investment returns. A company’s sale price or reported valuation is not the same as Cuban’s profit: his original cost, ownership, timing, taxes, and other proceeds matter, and those details are not fully available across his portfolio.
What counts as “most profitable” for Mark Cuban?
The public record supports comparing notable transaction events, not calculating a verified, portfolio-wide ranking of Cuban’s personal profits. The available figures are not apples-to-apples: they describe a company sale, a team purchase, and a later reported team valuation. They do not consistently disclose Cuban’s investment cost, ownership changes, distributions, or realized proceeds.
That distinction matters most for the headline numbers below. Broadcast.com’s reported $5.7 billion sale consideration was paid in stock to the company’s sellers; it is not a disclosed figure for Cuban’s personal proceeds. The Mavericks’ reported $3.5 billion valuation was not an official NBA disclosure and is not the amount Cuban personally received.
Broadcast.com: the clearest major exit
Cuban and Todd Wagner co-founded AudioNet, which became Broadcast.com. Cuban’s official biography says Broadcast.com went public in July 1998 and was sold to Yahoo for $5.7 billion in stock. That is the strongest documented headline exit among the examples covered here. Mark Cuban Companies’ biography
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
The $5.7 billion figure describes the sale consideration for the company, not Cuban’s net profit. His personal gain would depend on factors including his ownership at the time, when he sold or hedged shares, and taxes. The biography says he hedged his stock after the deal, but the available account does not supply enough detail to calculate his net realized return.
Dallas Mavericks: purchase price and later control sale
Cuban bought the Mavericks from Ross Perot Jr. for $285 million in 2000, according to the team’s December 2023 announcement. Dallas Mavericks announcement
Rank #2
In December 2023, the NBA approved the transfer of controlling interest in the team to the Adelson and Dumont families. NBA approval announcement
An Associated Press report carried by NBA.com put the deal in a $3.5 billion valuation range, citing an unnamed person with knowledge of the transaction. That was a reported valuation, not a sale price published in the NBA’s approval announcement. The same AP report said Cuban retained a 27% stake. The valuation therefore does not tell readers how much cash he received for the controlling-interest transaction, nor does it establish his eventual return on the team. Associated Press report carried by NBA.com
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallIn the team’s announcement, Cuban described the partnership in terms of complementary expertise: “They’re not basketball people,” he said. “I’m not real estate people. That’s why I did it.” Dallas Mavericks announcement
Cost Plus Drugs: a notable venture, with no public return figure
TIME reports that physician Alex Oshmyansky approached Cuban with a drug-pricing venture, Cuban invested, and the business launched as Cost Plus Drugs in 2022. The company’s cost-plus approach to generic medicines makes it a notable business venture, but the reporting does not disclose Cuban’s investment amount or realized return. It cannot be ranked as one of his most profitable investments on the available figures. TIME’s profile of Mark Cuban and Cost Plus Drugs
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Shark Tank: TV deals are not a verified returns list
Cuban’s official Shark Tank page confirms his role as one of the program’s featured Sharks and links to his companies portfolio. It does not provide audited, portfolio-wide gains and losses.
A deal proposed or agreed to on television should not automatically be treated as a completed investment or a successful exit. Without verified information about which deals closed, the capital invested, and subsequent outcomes, the on-air portfolio cannot support a reliable profit ranking.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Can we say how much Cuban made?
Not from these headline figures alone. The Broadcast.com sale consideration and the Mavericks’ reported valuation answer different questions, and neither is a complete accounting of Cuban’s personal proceeds or net profit. The available public material does not provide a consistent ledger of his costs, ownership, distributions, taxes, and realized gains across these ventures.
The careful conclusion is that Broadcast.com is the clearest documented large exit, while the Mavericks have a documented purchase price and a later reported valuation tied to a control sale. Cost Plus Drugs and Cuban’s Shark Tank activity are relevant parts of his business record, but the sources cited here do not establish their personal returns to him.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
